For the year ending 2025-12-31, ALBT had -$2,549,091 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Depreciation and amortization of intangible assets | 94,443 |
| Amortization of operating lease right-of-use asset | 64,388 |
| Stock-based compensation and service expense | 1,816,462 |
| Amortization of debt issuance costs and debt discount | 1,136,412 |
| Loss on extinguishment of debt | 9,076,587 |
| Security deposit | 17,491 |
| Prepaid expense and other assets | 22,299 |
| Accrued liabilities and other payables | 1,750,047 |
| Operating lease obligation | -64,388 |
| Change in fair market value of derivative liability | -538,213 |
| (income) loss from equity method investment | 392,677 |
| Income Loss From Equity Method Investments | 392,677 |
| Income from equity method investment - lab services mso | 392,677 |
| AIGenerated Polishing | 94,553 |
| Corporate Other | 7,889,483 |
| Other operating expenses | 7,984,036 |
| Interest Expense Nonoperating | 1,456,694 |
| Interest expense | 1,456,694 |
| Gains Losses On Extinguishment Of Debt | -9,076,587 |
| Loss on extinguishment of debt | -9,076,587 |
| Other income (expense) | 605,767 |
| Net loss from continuing operations | -17,518,873 |
| Distribution of earnings from equity method investment | 0 |
| Impairment of laboratory equipment | 0 |
| Debt modification charge | 0 |
| Accrued liabilities and other payables - related parties | 0 |
| Net cash used in operating activities from continuing operations | -4,580,620 |
| Cash acquired on acquisition | 14,026 |
| Proceeds from sale of equity method investment | 1,069,000 |
| Payment for equity interest purchase | 0 |
| Net cash provided by (used in) investing activities from continuing operations | 1,083,026 |
| Proceeds from issuance of convertible debt | 200,000 |
| Advance from pending sale of noncontrolling interest in subsidiary | 49,972 |
| Proceeds from issuance of convertible preferred stock | 300,000 |
| Payments of convertible preferred stock issuance costs | 10,000 |
| Proceeds from issuance of bridge loan | 300,000 |
| Proceeds from issuance of common stock and warrants | 475,500 |
| Payments of offering costs | 64,652 |
| Proceeds from stock subscription liability | 150,000 |
| Proceeds from issuance of convertible debt and warrants | 0 |
| Payments of convertible debt issuance costs | 0 |
| Repayments of convertible debt | 0 |
| Repayments of loan payable - related party | 0 |
| Proceeds from equity offering | 0 |
| Disbursements for equity offering costs | 0 |
| Net cash provided by financing activities from continuing operations | 1,400,820 |
| Net cash used in operating activities from discontinued operations | -407,434 |
| Net cash used in investing activities from discontinued operations | -35,865 |
| Net cash flows used in discontinued operations | -443,299 |
| Effect of exchange rate on cash - continuing operations | -9,018 |
| Net (decrease) increase in cash | -2,549,091 |
| Cash - beginning of year | 2,658,182 |
| Cash - end of year | 109,091 |
Avalon GloboCare Corp. (ALBT)
Avalon GloboCare Corp. (ALBT)